Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years of any gender
- People who are willing and able to give written consent to participate
- People who have a confirmed diagnosis of liver cancer (hepatocellular carcinoma), confirmed by imaging, tissue sample, or cell sample
- People who are willing to undergo a procedure called TACE (a treatment that delivers medicine directly to liver tumours through the blood vessels)
- People who are generally well enough to carry out light activity and care for themselves (a measure doctors use called ECOG performance status of 0–1)
- People who are expected to live for more than 3 months
- People whose blood test results at the screening visit fall within specific ranges for liver enzymes, blood clotting, blood cell counts, bilirubin, and kidney function (confirm with trial site for exact values)
- People whose liver shows a certain level of stiffness on a specialist liver scan, indicating some degree of liver scarring or fibrosis (confirm with trial site)
Who may not be able to join:
- People whose cancer has spread into major blood vessels of the liver
- People whose cancer has spread to areas outside the liver
- People for whom the TACE procedure would be considered medically unsuitable by the treating doctors
- People with acute liver failure or signs that the liver is no longer functioning adequately, such as confusion caused by liver disease or significant fluid build-up in the abdomen
- People with active hepatitis B or C infection who are recommended to receive antiviral treatment (for example, people with hepatitis B virus levels of 20,000 IU/mL or higher, or detectable hepatitis C virus in their blood)
- People with serious disease affecting the heart, lungs, brain, kidneys, or digestive system, as judged by the trial doctors
- People with chronic pancreatitis (long-term inflammation of the pancreas)
- People who are taking certain medications that could interfere with the trial (confirm with trial site for the specific list)
- People who are unable to communicate their symptoms or health concerns, for example due to psychosis or severe neurological conditions
- People who have had an active infection requiring antibiotics within the 4 weeks before their screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kai-Wen Huang, MD, MS, PhD, National Taiwan University Hospital
Phone: 886-2-2627-5585
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in the level of liver function
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.